关注新型冠状病毒感染后重症皮肤病

doi:10.35541/cjd.20230339

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (4): 378-383.doi: 10.35541/cjd.20230339

• 综述 • 上一篇

关注新型冠状病毒感染后重症皮肤病

李紫钰鲁严

南京医科大学第一附属医院皮肤科，南京 210029

收稿日期:2023-06-14 修回日期:2024-08-18 发布日期:2025-04-03
通讯作者: 鲁严 E-mail:luyan6289@163.com
基金资助:
国家自然科学基金（82273549）

Paying attention to severe skin diseases after COVID-19

Li Ziyu, Lu Yan

Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Received:2023-06-14 Revised:2024-08-18 Published:2025-04-03
Contact: Lu Yan E-mail:luyan6289@163.com
Supported by:
National Natural Science Foundation of China（82273549）

摘要/Abstract

摘要： 【摘要】新型冠状病毒感染暴发后，全球出现了许多与该病毒相关或继发的皮肤疾病，其感染会诱发皮肤病及其他系统症状的出现或加重。本文旨在探讨新型冠状病毒感染后重症皮肤疾病如系统性红斑狼疮、重症银屑病、天疱疮、皮肌炎、白塞综合征等皮肤病的表现及处置，以期提升新型冠状病毒感染后重症皮肤病的诊疗水平。

关键词: 新型冠状病毒感染, 重症皮肤病, 治疗, 红斑狼疮, 系统性, 银屑病, 天疱疮, 皮肌炎

Abstract: 【Abstract】 Since the outbreak of COVID-19, many skin diseases related to or secondary to COVID-19 have been reported globally, and the infection can trigger or exacerbate skin diseases and other systemic symptoms. The review aims to discuss the manifestations and management of severe skin diseases following COVID-19, such as systemic lupus erythematosus, severe psoriasis, pemphigus, dermatomyositis, and Beh?et's syndrome, with the goal of improving the diagnosis and treatment of severe skin diseases after COVID-19.

Key words: COVID-19, Severe skin disease, Therapy, Lupus erythematosus, systemic, Psoriasis, Pemphigus, Dermatomyositis

李紫钰鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025,58(4):378-383. doi:10.35541/cjd.20230339

Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19[J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.doi:10.35541/cjd.20230339

参考文献 63

［1］	鲁严, 骆丹, 张美华. 危重皮肤病救治［M］. 北京: 人民卫生出版社, 2013.
［2］	Mohaghegh F, Hatami P, Refaghat A, et al. New⁃onset pemphigus foliaceus following SARS⁃CoV⁃2 infection and unmasking multiple sclerosis: a case report［J］. Clin Case Rep, 2022,10（6）:e05910. doi: 10.1002/ccr3.5910.
［3］	Narang I, Panthagani AP, Lewis M, et al. COVID⁃19⁃induced toxic epidermal necrolysis［J］. Clin Exp Dermatol, 2021,46（5）:927⁃929. doi: 10.1111/ced.14574.
［4］	Fernandez⁃Ruiz R, Paredes JL, Niewold TB. COVID⁃19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease［J］. Transl Res, 2021,232:13⁃36. doi: 10.1016/j.trsl.2020.12.007.
［5］	Tsang⁃A⁃Sjoe M, Bultink I. New developments in systemic lupus erythematosus［J］. Rheumatology （Oxford）, 2021,60（Suppl 6）:vi21⁃vi28. doi: 10.1093/rheumatology/keab498.
［6］	Gianfrancesco M, Hyrich KL, Al⁃Adely S, et al. Characteristics associated with hospitalisation for COVID⁃19 in people with rheumatic disease: data from the COVID⁃19 Global Rheumatology Alliance physician⁃reported registry［J］. Ann Rheum Dis, 2020,79（7）:859⁃866. doi: 10.1136/annrheumdis⁃2020⁃217871.
［7］	Bennardo L, Nisticò SP, Dastoli S, et al. Erythema multiforme and COVID⁃19: what do we know?［J］. Medicina （Kaunas）, 2021,57（8）:828. doi: 10.3390/medicina57080828.
［8］	Ruiz⁃Ordóñez I, Santos VA, Bonilla⁃Abadía F, et al. Lymphoid follicular hyperplasia in patients with systemic lupus erythematosus after multiple cycles of rituximab［J］. Mod Rheumatol Case Rep, 2023,7（1）:78⁃81. doi: 10.1093/mrcr/rxac066.
［9］	Levy G, Guglielmelli P, Langmuir P, et al. JAK inhibitors and COVID⁃19［J］. J Immunother Cancer, 2022,10（4）:e002838. doi: 10.1136/jitc⁃2021⁃002838.
［10］	Zhou B, Li S, Ye J, et al. Immunopathological events surrounding IL⁃6 and IFN⁃α: a bridge for anti⁃lupus erythematosus drugs used to treat COVID⁃19［J］. Int Immunopharmacol, 2021,101（Pt B）:108254. doi: 10.1016/j.intimp.2021.108254.
［11］	Mason A, Rose E, Edwards CJ. Clinical management of Lupus patients during the COVID⁃19 pandemic［J］. Lupus, 2020,29（13）:1661⁃1672. doi: 10.1177/0961203320961848.
［12］	Goyal PK, Mohammed TO, Mahmoud A, et al. COVID⁃19 infection leading to acute pustular dermatoses［J］. Arch Dermatol Res, 2023,315（4）:685⁃697. doi: 10.1007/s00403⁃022⁃02450⁃z.
［13］	Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID⁃19: Will cases of psoriasis increase after COVID⁃19 pandemic?［J］. Dermatol Ther, 2020,33（4）:e13383. doi: 10.1111/dth.13383.
［14］	Shakoei S, Ghanadan A, Hamzelou S. Pustular psoriasis exacerbated by COVID⁃19 in a patient with the history of psoriasis［J］. Dermatol Ther, 2020,33（6）:e14462. doi: 10.1111/dth.14462.
［15］	Shahidi Dadras M, Diab R, Ahadi M, et al. Generalized pustular psoriasis following COVID⁃19［J］. Dermatol Ther, 2021,34（1）:e14595. doi: 10.1111/dth.14595.
［16］	Peng G, Okumura K, Ogawa H, et al. Psoriatic lesional expression of SARS⁃CoV⁃2 receptor ACE2 is reduced by blockade of IL⁃17 signaling but not by other biologic treatments［J］. J Am Acad Dermatol, 2022,87（3）:714⁃715. doi: 10.1016/j.jaad.2022.01.041.
［17］	Xu Q, Chen L, Li X, et al. If skin is a potential host of SARS⁃CoV⁃2, IL⁃17 antibody could reduce the risk of COVID⁃19［J］. J Am Acad Dermatol, 2021,84（3）:e173. doi: 10.1016/j.jaad.2020. 10.084.
［18］	Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID⁃19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience［J］. Br J Dermatol, 2020,183（2）:373⁃374. doi: 10.1111/bjd.19158.
［19］	Kamal K, Riew GJ, Hijaz B, et al. Generalized pustular psoriasis⁃like widespread eruption following COVID⁃19 infection in a patient with spondyloarthropathy on adalimumab［J］. Exp Dermatol, 2024,33（1）:e14889. doi: 10.1111/exd.14889.
［20］	Samotij D, Gawron E, Szczęch J, et al. Acrodermatitis continua of hallopeau evolving into generalized pustular psoriasis following COVID⁃19: a case report of a successful treatment with infliximab in combination with acitretin［J］. Biologics, 2021,15:107⁃113. doi: 10.2147/BTT.S302164.
［21］	Sadeghinia A, Daneshpazhooh M. Immunosuppressive drugs for patients with psoriasis during the COVID⁃19 pandemic era. A review［J］. Dermatol Ther, 2021,34（1）:e14498. doi: 10.1111/dth.14498.
［22］	Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID⁃19 pandemic［J］. J Dermatolog Treat, 2020,31（4）:317⁃318. doi: 10.1080/09546634.2020.1742438.
［23］	Wang G, Gu H,Zheng M, et al.Experts opinion on the use of biologic agents in psoriatic patients during COVID⁃19 outbreak［J］. Int J Dermatol Venerol, 2020,3（2）:68⁃69. doi:10.1097/JD9. 0000000000000097.
［24］	Agharbi FZ, Basri G, Nejjari S, et al. Erythrodermic psoriasis following SARS⁃CoV⁃2 infection［J］. Actas Dermosifiliogr, 2024,115（2）:202⁃203. doi: 10.1016/j.ad.2022.07.014.
［25］	Mugheddu C, Pizzatti L, Sanna S, et al. COVID⁃19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:e376⁃e378. doi: 10.1111/jdv.16625.
［26］	Zhang L, Guo L, Wang L, et al. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis ⁃ a network meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1937⁃1946. doi: 10.1111/jdv.18263.
［27］	Kim YH, Kang HY. Pemphigus vulgaris possibly associated with COVID⁃19 infection［J］. Cureus, 2023,15（1）:e33897. doi: 10.7759/cureus.33897.
［28］	Joly P, Maho⁃Vaillant M, Prost⁃Squarcioni C, et al. First⁃line rituximab combined with short⁃term prednisone versus prednisone alone for the treatment of pemphigus （Ritux 3）: a prospective, multicentre, parallel⁃group, open⁃label randomised trial［J］. Lancet, 2017,389（10083）:2031⁃2040. doi: 10.1016/S0140⁃6736（17）30070⁃3.
［29］	Kasperkiewicz M, Woodley DT. Association between vaccination and autoimmune bullous diseases: a systematic review［J］. J Am Acad Dermatol, 2022,86（5）:1160⁃1164. doi: 10.1016/j.jaad. 2021.04.061.
［30］	Breglio KF, Sarver MM, Hall RP 3rd, et al. SARS⁃CoV⁃2 infections in patients with autoimmune blistering disorders: A case series and retrospective analysis［J］. JAAD Int, 2022,7:38⁃43. doi: 10.1016/j.jdin.2022.01.003.
［31］	Uzuncakmak TK, Özkoca D, Askin O, et al. Can rituximab be used in the treatment of pemphigus vulgaris during the COVID⁃19 pandemic?［J］. Dermatol Ther, 2021,34（1）:e14647. doi: 10.1111/dth.14647.
［32］	Banciu ML, Dobrica C, Malciu AM, et al. Diagnosis and treatment challenges of an atypical case of pemphigus vulgaris during the COVID⁃19 pandemic［J］. Cureus, 2022,14（1）:e21739. doi: 10.7759/cureus.21739.
［33］	EULAR guidance for patients Covid⁃19 outbreak \| EULAR［EB/OL］. ［2024⁃08⁃18］. https://www.eular.org/eular⁃guidance⁃for⁃patients⁃covid19⁃outbreak.
［34］	Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon⁃alpha/beta⁃mediated innate immune mechanisms in dermatomyositis［J］. Ann Neurol, 2005,57（5）:664⁃678. doi: 10.1002/ana.20464.
［35］	Kondo Y, Kaneko Y, Takei H, et al. COVID⁃19 shares clinical features with anti⁃melanoma differentiation⁃associated protein 5 positive dermatomyositis and adult Still's disease［J］. Clin Exp Rheumatol, 2021,39（3）:631⁃638. doi: 10.55563/clinexprheumatol/ 44kaji.
［36］	Saud A, Naveen R, Aggarwal R, et al. COVID⁃19 and myositis: what we know so far［J］. Curr Rheumatol Rep, 2021,23（8）:63. doi: 10.1007/s11926⁃021⁃01023⁃9.
［37］	Gokhale Y, Patankar A, Holla U, et al. Dermatomyositis during COVID⁃19 pandemic （a case series）: is there a cause effect relationship?［J］. J Assoc Physicians India, 2020, 68（11）: 20⁃24.
［38］	Lakota K, Perdan⁃Pirkmajer K, Hočevar A, et al. COVID⁃19 in association with development, course, and treatment of systemic autoimmune rheumatic diseases［J］. Front Immunol, 2020,11:611318. doi: 10.3389/fimmu.2020.611318.
［39］	Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid⁃19［J］. N Engl J Med, 2021,384（9）:795⁃807. doi: 10.1056/NEJMoa2031994.
［40］	鲁锦玥, 沈海丽. 托法替布治疗MDA5阳性皮肌炎出现快速进展型间质性肺病1例［DB/OL］. 中国临床案例成果数据库, 2023,5（1）：E00021⁃E00021.doi:10.3760/cma.j.cmcr.2023.e00021.
［41］	Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis⁃associated interstitial lung disease［J］. N Engl J Med, 2019,381（3）:291⁃293. doi: 10.1056/NEJMc1900045.
［42］	Pagh P, Rossau A⁃K. COVID⁃19⁃induced Stevens⁃Johnson syndrom［J］. Ugeskrift for Laeger, 2022,184（10）:V10210804.
［43］	Emadi SN, Hamzelou S, Saffarian Z, et al. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID⁃19: a case report［J］. Dermatol Ther, 2021,34（1）:e14656. doi: 10.1111/dth.14656.
［44］	Saha M, D'Cruz A, Paul N, et al. Toxic epidermal necrolysis and co⁃existent SARS⁃CoV⁃2 （COVID⁃19） treated with intravenous immunoglobulin: 'Killing 2 birds with one stone'［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:e97⁃e98. doi: 10.1111/jdv. 16887.
［45］	谢小慧, 陈辉. 新型冠状病毒肺炎合并Stevens⁃Johnson综合征样皮损一例［J］. 中华皮肤科杂志, 2020,53（8）:649⁃650. doi: 10.35541/cjd.20200228.
［46］	Shahidi⁃Dadras M, Araghi F, Ahmadzadeh A, et al. TEN/SJS⁃like lupus erythematosus presentation complicated by COVID⁃19［J］. Dermatol Ther, 2021,34（1）:e14612. doi: 10.1111/dth.14612.
［47］	Robustelli Test E, Vezzoli P, Carugno A, et al. Acute generalized exanthematous pustulosis with erythema multiforme⁃like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 （COVID⁃19）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:e457⁃e459. doi: 10.1111/jdv.16613.
［48］	Cruz VB, Júnior L, Kobal CR, et al. Does sensitization by SARS⁃CoV⁃2 immune complexes trigger DRESS syndrome?［J］. Braz J Infect Dis, 2022,26（2）:102337. doi: 10.1016/j.bjid.2022.102337.
［49］	Balconi SN, Lopes NT, Luzzatto L, et al. Detection of SARS⁃CoV⁃2 in a case of DRESS by sulfasalazine: could there be a relationship with clinical importance?［J］. Int J Dermatol, 2021,60（1）:125⁃126. doi: 10.1111/ijd.15316.
［50］	Roujeau JC, Dupin N. Virus reactivation in drug reaction with eosinophilia and systemic symptoms （Dress） results from a strong drug⁃specific immune response［J］. J Allergy Clin Immunol Pract, 2017,5（3）:811⁃812. doi: 10.1016/j.jaip.2016. 11.027.
［51］	Ramirez GA, Della⁃Torre E, Tresoldi M, et al. Drug reaction with eosinophilia and systemic symptoms （DRESS） in patients with COVID⁃19［J］. Clin Microbiol Infect, 2021,27（8）:1190⁃1192. doi: 10.1016/j.cmi.2021.05.023.
［52］	Manjaly Thomas ZR, Leuppi⁃Taegtmeyer A, Jamiolkowski D, et al. Emerging treatments in COVID⁃19: adverse drug reactions including drug hypersensitivities［J］. J Allergy Clin Immunol, 2020,146（4）:786⁃789. doi: 10.1016/j.jaci.2020.07.008.
［53］	Elmas ÖF, Demirbaş A, Bağcıer F, et al. Treatment considerations for Behçet disease in the era of COVID⁃19: a narrative review［J］. Dermatol Ther, 2021,34（1）:e14507. doi: 10.1111/dth.14507.
［54］	Nas K, Dilek G, Kalçık Unan M, et al. The clinical outcomes of COVID⁃19 in patients with Behçet's disease: a series of 7 cases and brief review of the literature［J］. Eurasian J Med, 2022,54（3）:305⁃309. doi: 10.5152/eurasianjmed.2021.21203.
［55］	Hendry BM, Stafford N, Arnold AD, et al. Hypothesis: pentoxifylline is a potential cytokine modulator therapeutic in COVID⁃19 patients［J］. Pharmacol Res Perspect, 2020,8（4）:e00631. doi: 10.1002/prp2.631.
［56］	Trevisini S, Trevisan G, Zalaudek I, et al. Adamantiades⁃Behçet's disease therapy: current treatment options and recommendations with regard to the COVID⁃19 pandemic［J］. Dermatol Ther, 2022,35（3）:e15286. doi: 10.1111/dth.15286.
［57］	Dursun R, Temiz SA, Özer İ, et al. Management of patients with Behçet's disease during the COVID⁃19 pandemic［J］. Dermatol Ther, 2020,33（6）:e14063. doi: 10.1111/dth.14063.
［58］	Mashayekhi F, Seirafianpour F, Pour Mohammad A, et al. Severe and life⁃threatening COVID⁃19⁃related mucocutaneous eruptions: a systematic review［J］. Int J Clin Pract, 2021,75（12）:e14720. doi: 10.1111/ijcp.14720.
［59］	Dotan A, Muller S, Kanduc D, et al. The SARS⁃CoV⁃2 as an instrumental trigger of autoimmunity［J］. Autoimmun Rev, 2021,20（4）:102792. doi: 10.1016/j.autrev.2021.102792.
［60］	Zhang S, Liu Y, Wang X, et al. SARS⁃CoV⁃2 binds platelet ACE2 to enhance thrombosis in COVID⁃19［J］. J Hematol Oncol, 2020,13（1）:120. doi: 10.1186/s13045⁃020⁃00954⁃7.
［61］	Levy JH, Iba T, Olson LB, et al. COVID⁃19: thrombosis, thromboinflammation, and anticoagulation considerations［J］. Int J Lab Hematol, 2021,43 Suppl 1（Suppl 1）:29⁃35. doi: 10.1111/ijlh.13500.
［62］	Calabretta E, Moraleda JM, Iacobelli M, et al. COVID⁃19⁃induced endotheliitis: emerging evidence and possible therapeutic strategies［J］. Br J Haematol, 2021,193（1）:43⁃51. doi: 10.1111/bjh.17240.
［63］	Teuwen LA, Geldhof V, Pasut A, et al. COVID⁃19: the vasculature unleashed［J］. Nat Rev Immunol, 2020,20（7）:389⁃391. doi: 10.1038/s41577⁃020⁃0343⁃0.

[1]	包诗杰韩梅周小勇. 基于文献回顾的依那西普治疗中毒性表皮坏死松解症疗效影响因素分析[J]. 中华皮肤科杂志, 2025, 58(4): 352-355.
[2]	万勇军杨海晶严翘陈梅王逢源粟倩雅董正邦王飞. 免疫检查点抑制剂相关Stevens-Johnson综合征/中毒性表皮坏死松解症9例临床及预后分析[J]. 中华皮肤科杂志, 2025, 58(4): 347-351.
[3]	中国医师协会皮肤科医师分会儿童学组中华医学会皮肤性病学分会银屑病学组. 【开放获取】儿童脓疱型银屑病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 297-306.
[4]	何春霞晋红中. 【开放获取】急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314.
[5]	木葵郭慧文海泉龙海刘昱罗帅寒天黄馨周星雨肖嵘李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327.
[6]	叶鸣昱施雁庭黎皓项捷王松曹华. 血清半乳糖凝集素9水平在评估皮肌炎合并肿瘤中的临床意义[J]. 中华皮肤科杂志, 2025, 58(4): 328-333.
[7]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国医疗保健国际交流促进会皮肤医学分会中国罕见病联盟皮肤罕见病专业委员会国家皮肤与免疫疾病临床医学研究中心. 【开放获取】副肿瘤性天疱疮诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 289-296.
[8]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 特应性皮炎达标门诊建设标准专家共识（2025基层版）[J]. 中华皮肤科杂志, 2025, 0(4): 20240296-e20240296.
[9]	许秋云纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 中华皮肤科杂志, 2025, 58(4): 369-373.
[10]	吕铭悦满孝勇. 细胞治疗在系统性红斑狼疮中的应用[J]. 中华皮肤科杂志, 2025, 58(4): 374-377.
[11]	王雪颖王真真王喆糜自豪孙乐乐刘红张福仁. 中国汉族家族性良性慢性天疱疮患者的功能丧失突变与较早的发病年龄相关[J]. 中华皮肤科杂志, 2025, 58(3): 221-227.
[12]	陈瑶余浪姜倩喻惠元陈柳青陈金波. 大疱性类天疱疮和天疱疮光学相干断层扫描成像特征比较[J]. 中华皮肤科杂志, 2025, 58(3): 216-220.
[13]	陈启韬李煜乾邵光辉朱晶朱麒麟李中明杜旭峰范卫新. 头皮糜烂性脓疱性皮病研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 272-275.
[14]	李秀珍徐秀莲. 白细胞介素23抑制剂治疗对银屑病共病的影响[J]. 中华皮肤科杂志, 2025, 58(3): 268-272.
[15]	陈良宏孙艳王敬玉吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268.

关注新型冠状病毒感染后重症皮肤病

Paying attention to severe skin diseases after COVID-19

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 63

相关文章 15

Metrics

本文评价

推荐阅读 10